Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 4 1Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 36Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Pancreatic Neoplasms 4Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Advanced Breast Cancer 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Inflammation 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombosis 1Thromboembolism 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Primary Myelofibrosis 1Oligodendroglioma 1Neoplasms, Neuroepithelial 1Myeloproliferative Disorders 1

Interventions

pembrolizumab 23Paclitaxel 20Carboplatin 18Taxes 7temsirolimus 6Trastuzumab 6Topotecan 5Radiotherapy 5atezolizumab 4Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Gemcitabine 4Docetaxel 4Cisplatin 4Biopsy 4Bevacizumab 4olaparib 3lenvatinib 3dostarlimab 3Sirolimus 3Pemetrexed 3Irinotecan 3Interleukin-12 Subunit p35 3Fulvestrant 3Cetuximab 3Albumin-Bound Paclitaxel 3spartalizumab 2gedatolisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Endometrial Neoplasms × palbociclib × Clear all
NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡